Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin

Ming Han Tsai, Yhu Chering Huang, Meng Hsiu Yen, Chung Chen Li, Cheng Hsun Chiu, Pen Yi Lin, Tzou Yien Lin, Luan Yin Chang

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)


Objective: To determine whether different brands of intravenous immunoglobulin (IVIG) administered to children with Kawasaki disease (KD) result in different outcomes. Study design: We analyzed children with KD and divided them into 4 groups according to the brand of IVIG. A coronary artery abnormality (CAA) was defined as having a lumen diameter (inner border to inner border) of ≥3 mm in KD cases <5 years old and ≥4 mm in cases ≥5 years old, and giant aneurysm was defined as a lumen diameter ≥8 mm. Patients were considered nonresponsive to IVIG therapy if fever persisted longer than 2 days after completion of treatment and needed retreatment with IVIG. Results: We collected 437 cases, 29 (6.6%) were nonresponsive, 17 (3.9%) had CAA at convalescence, and 3 (0.7%) had giant aneurysm, 2 of whom had development of myocardial infarcts. Patients receiving Brand C IVIG, prepared with β-propiolactone, had higher rates (10%, 9/93, P = .01) of CAA at convalescence and nonresponsiveness (13%, 12/93, P = .001); giant aneurysm occurred in 3/93 (3%) receiving Brand C IVIG and in 0/344 who received the other 3 brands (P = .008). Conclusions: IVIG, prepared with β-propiolactone, was most significantly associated with nonresponsiveness, CAA at convalescence, and giant aneurysm. Physicians should be cautious when using IVIG prepared with β-propiolactone or enzyme digestion to treat KD.

Original languageEnglish
Pages (from-to)38-43
Number of pages6
JournalJournal of Pediatrics
Issue number1
Publication statusPublished - Jan 2006
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin'. Together they form a unique fingerprint.

Cite this